期刊文献+

CA125的生物素-亲和素酶联免疫检测方法的建立 被引量:3

暂未订购
导出
摘要 目的:建立CA125的生物素-亲和素酶联免疫检测(BA-ELISA)方法,进行方法学评价。方法:纯化卵巢癌患者腹水得到CA125抗原,制备生物素化CA125抗体,酶标板包被生物素化BSA,建立BA-ELISA反应系统。观察本方法的灵敏度、回收率、特异度、稳定性等指标。测定卵巢癌患者以及卵巢良性肿瘤患者血清CA125水平,与化学发光免疫检测结果对比。结果:BA-ELISA方法灵敏度为3.18U/L,与CEA、PSA等交叉反应率低;高低浓度样品平均回收率分别为107.11%、99.96%,批内和批间变异分别为7.97%、8.04%,稳定性好。本研究与化学发光免疫检测检出结果差异无统计学意义,检测卵巢癌患者血清CA125水平,回归方程为y=-6.830+1.014x,r=0.993。检测卵巢良性肿瘤患者血清CA125水平,回归方程为y=1.936+0.937x,r=0.986。结论:BA-ELISA检测方法的建立在诊断卵巢癌等方面灵敏度高、特异性强,操作简便,无需昂贵仪器,适合广泛应用。
出处 《实用医学杂志》 CAS 北大核心 2011年第9期1675-1678,共4页 The Journal of Practical Medicine
  • 相关文献

参考文献9

  • 1Bast R C Jr,Klug T L,St John E,et al.A radioimmuno-assay using a monoclonal antibody to monitor the course of epithelial ovarian cancer[J].N Engl J Med,1983,309(15):883-887.
  • 2Wattanaphansak S,Asawakarn T,Gebhart C J,et al.Development and validation of an enzyme-linked immunosorbent assay for the diagnosis of porcine proliferative enteropathy[J].J Vet Diagn Invest,2008,20(2):170-177.
  • 3Parkin D M.The role of cancer registries in cancer control[J].Int J Clin Oncol,2008,13(2):102-111.
  • 4Cramer D W,O′Rourke D J,Vitonis A F,et al.CA125 immune complexes in ovarian cancer patients with low CA125 concentrations[J].Clin Chem,2010,56(12):1889-1892.
  • 5Prat A,Parera M,Adamo B,et al.Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels[J].Ann Oncol,2009,20(2):294-297.
  • 6Kim K H,Shim J H,Cho M C,et al.Development of enzyme linked immunosorbent assay for erythropoietin[J].Korean J Lab Med,2006,26(3):185-191.
  • 7孙琦,谢服役,郑美娜.Architect i2000免疫分析仪测定血清肿瘤标志物甲胎蛋白、CA125的初步评价[J].实用医学杂志,2009,25(1):138-140. 被引量:2
  • 8孔令青,李勇,高洪,严玉霖.生物素-亲和素标记技术[J].动物医学进展,2008,29(4):100-102. 被引量:22
  • 9李金明.临床酶免疫测定技术[M].北京:人民军医出版社,2006.89

二级参考文献20

共引文献49

同被引文献37

  • 1李镒冲,李晓松.两种测量方法定量测量结果的一致性评价[J].现代预防医学,2007,34(17):3263-3266. 被引量:160
  • 2Lloyd KO, Yin BW,Kudryashov V. Isolation and charac- terization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8) : Identification as a mucin type molecule[J]. Int J Cancer, 1997,71 ( 5 ) : 842-850.
  • 3Nakata B, Hirakawa-YS Chung K, Kato Y, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma[J]. Cancer,1998,83(12) : 2488-2492.
  • 4Berthiot G, Marechal F, Cattan A, et al. Serum levels of CA-50,CA-19. 9, CA 125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign disea- ses of the lung[J]. Biomed Pharmacother, 1989,43 (8): 613-620.
  • 5Acin P, Besses C, Centelles M, et al. Elevated serum CA125 tumor marker in chronic lymphocytic leukemia with mesothelial involvement[J]. Am J Hematol, 1996, 53(4) :281.
  • 6Mongia SK, Rawlins ML, Owen WE, et al. Performance characteristics of seven automated CA 125 assays[J]. Am J Clin Pathol,2006,125(6):921-927.
  • 7Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma [J]. J Clin Invest, 1981, 68 (5): 1331-1337.
  • 8Lloyd KO, Yin BW, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK- 8): identification as a mucin-type molecule[J]. IntJ Cancer, 1997, 71(5): 842-850.
  • 9Nakata B, Hirakawa-YS Chung K, Kato Y, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma[J]. Cancer, 1998, 83(12): 2488-2492.
  • 10Berthiot G, Marechal F, Cattan A, et al. Serum levels of CA-S0, CA- 19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of the lung[J]. Biomed Pharmacother, 1989, 43(8): 613-620.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部